Literature DB >> 16309912

Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.

Minoru Ishikawa1, Dai Kubota, Mikio Yamamoto, Chizuko Kuroda, Maki Iguchi, Akihiro Koyanagi, Shoichi Murakami, Keiichi Ajito.   

Abstract

We synthesized 4-aminopiperidine derivatives of our prototype integrin alpha(v)beta3 antagonist 1 in an attempt to increase the activity and water solubility. Introduction of one or two hydrophilic moieties into the central aromatic ring and/or the benzene ring at the C-terminus of 1 increased water solubility and enhanced inhibition of cell adhesion. The results of a structure-activity relationships (SAR) study indicated that the torsion angle between the central aromatic ring and the piperidine ring, and the acidity at the sulfonamide moiety, might be important for alpha(v)beta3 receptor binding activity. Some of these compounds are novel and potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists with acceptable water solubility and a satisfactory early absorption, distribution, metabolism, excretion, and toxicity (ADMET) profile.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16309912     DOI: 10.1016/j.bmc.2005.10.061

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Cross-Talk between Transforming Growth Factor-β and Periostin Can Be Targeted for Pulmonary Fibrosis.

Authors:  Yasuhiro Nanri; Satoshi Nunomura; Yasuhiro Terasaki; Tomohito Yoshihara; Yusuke Hirano; Yasuyuki Yokosaki; Yukie Yamaguchi; Carol Feghali-Bostwick; Keiichi Ajito; Shoichi Murakami; Simon J Conway; Kenji Izuhara
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

2.  Improvement in aqueous solubility of achiral symmetric cyclofenil by modification to a chiral asymmetric analog.

Authors:  Junki Morimoto; Kazunori Miyamoto; Yuki Ichikawa; Masanobu Uchiyama; Makoto Makishima; Yuichi Hashimoto; Minoru Ishikawa
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.